Antigen-based immunotherapy (AIT) for autoimmune and allergic disease

Macleod, M. K.L. and Anderton, S. M. (2015) Antigen-based immunotherapy (AIT) for autoimmune and allergic disease. Current Opinion in Pharmacology, 23, pp. 11-16. (doi: 10.1016/j.coph.2015.05.003) (PMID:26004365)

Abstract

Autoimmune and allergic diseases are major causes of morbidity. Antigen-based immunotherapy (AIT) is immunologically the most satisfying means of specifically targeting only those T cells driving disease, thereby inducing antigen-specific immune tolerance, with the lowest adverse risk profile. AIT is highly effective in rodent models of T cell-driven inflammation and is now in clinical trials. The range of approaches to applying AIT in the clinic prevents a consensus on the molecular basis for this form of tolerance. In particular, there has been a paucity of information on how pre-activated effector and memory T cells respond to AIT. New, advanced murine models of AIT are beginning to deliver such information at the cellular, biochemical, transcriptional and epigenetic levels.

• Item Type: Articles
• Status: Published
• Refereed: Yes
• Glasgow Author(s) Enlighten ID: Macleod, Dr Megan
• Authors: Macleod, M. K.L., and Anderton, S. M.
• College/School: College of Medical Veterinary and Life Sciences > School of Infection & Immunity
• Journal Name: Current Opinion in Pharmacology
• Publisher: Elsevier Ltd.
• ISSN: 1471-4892
• ISSN (Online): 1471-4973
• Copyright Holders: Copyright © 2015 The Authors
• First Published: First published in Current Opinion in Pharmacology 23:11-16
• Publisher Policy: Reproduced under a Creative Commons License